Performance of 6 HCV genotyping 9G test for HCV genotyping in clinical samples

Abstract Background A treatment of HCV infection depends on the genotype and sub-genotype. Therefore, accurate HCV genotyping is critical for selecting the appropriate treatment regimen. Method This study included 280 plasma samples to evaluate the performance of 6 HCV Genotyping 9G test. The perfor...

Full description

Bibliographic Details
Main Authors: Shrikant Dasharath Warkad, Satish Balasaheb Nimse, Keum-Soo Song, Wasun Chantratita, Viroj Pongthanapisith, Laxman Uddhav Nawale, Taisun Kim
Format: Article
Language:English
Published: BMC 2018-07-01
Series:Virology Journal
Subjects:
HCV
Online Access:http://link.springer.com/article/10.1186/s12985-018-1017-4
id doaj-681b49f31f5d435b9765b9b7a06352b4
record_format Article
spelling doaj-681b49f31f5d435b9765b9b7a06352b42020-11-24T21:24:04ZengBMCVirology Journal1743-422X2018-07-011511710.1186/s12985-018-1017-4Performance of 6 HCV genotyping 9G test for HCV genotyping in clinical samplesShrikant Dasharath Warkad0Satish Balasaheb Nimse1Keum-Soo Song2Wasun Chantratita3Viroj Pongthanapisith4Laxman Uddhav Nawale5Taisun Kim6Institute for Applied Chemistry and Department of Chemistry, Hallym UniversityInstitute for Applied Chemistry and Department of Chemistry, Hallym UniversityInstitute for Applied Chemistry and Department of Chemistry, Hallym UniversityDepartment of Pathology, Faculty of Medicine, Virology Laboratory, Ramathibodi Hospital, Mahidol UniversityDepartment of Pathology, Faculty of Medicine, Virology Laboratory, Ramathibodi Hospital, Mahidol UniversityInstitute for Applied Chemistry and Department of Chemistry, Hallym UniversityInstitute for Applied Chemistry and Department of Chemistry, Hallym UniversityAbstract Background A treatment of HCV infection depends on the genotype and sub-genotype. Therefore, accurate HCV genotyping is critical for selecting the appropriate treatment regimen. Method This study included 280 plasma samples to evaluate the performance of 6 HCV Genotyping 9G test. The performance of 6 HCV Genotyping 9G test for accurate detection of HCV 1a, 1b, 2, 3, 4, and 6 genotypes was evaluated by comparing it with LiPA 2.0 assay and sequencing. Results 6 HCV Genotyping 9G test and LiPA 2.0 assay demonstrated 83.9% (n = 235) agreement. 39/45 samples that showed discrepant results between the two tests were analyzed by sequencing. Sequencing genotyped 39 discrepant samples as 0 (HCV 1a), 24 (HCV 1b), 1 (HCV 6f), 12 (HCV 6i), and 2 (HCV-negative). Results of 6 HCV Genotyping 9G test were very similar to the sequencing as it detected 1, 23, 1, 12, and 2 samples as HCV 1a, 1b, 3 & 6a or 6f, 6i or 6n, and negative, respectively. However, LiPA 2.0 assay showed complete disagreement with sequencing, as it did not detect any of these 39 samples correctly. These results indicate that LiPA 2.0 assay has limitations in identifying HCV genotypes 1b, and 6. The sensitivity, specificity, PPV, and NPV of 6 HCV Genotyping 9G test were 99.5, 98.8, 99.5, and 98.8%, respectively. It is important to note that HCV Genotyping 9G test showed 98.3 and 100% sensitivity for HCV 1b and 6 genotyping, respectively. However, LiPA 2.0 assay demonstrated 57.9 and 71.7% sensitivity for these genotypes. Conclusions 6 HCV Genotyping 9G test identifies HCV 1a, 1b, 2, 3, and 6 with good agreement with sequencing. Hence, 6 HCV Genotyping 9G test has a high clinical value because it can provide critical information to physicians and assist them to use the correct drug for efficient hepatitis C treatment.http://link.springer.com/article/10.1186/s12985-018-1017-4HCVHCV genotyping9G DNA technologyINNO-LiPA, liver cirrhosis, hepatocellular carcinoma
collection DOAJ
language English
format Article
sources DOAJ
author Shrikant Dasharath Warkad
Satish Balasaheb Nimse
Keum-Soo Song
Wasun Chantratita
Viroj Pongthanapisith
Laxman Uddhav Nawale
Taisun Kim
spellingShingle Shrikant Dasharath Warkad
Satish Balasaheb Nimse
Keum-Soo Song
Wasun Chantratita
Viroj Pongthanapisith
Laxman Uddhav Nawale
Taisun Kim
Performance of 6 HCV genotyping 9G test for HCV genotyping in clinical samples
Virology Journal
HCV
HCV genotyping
9G DNA technology
INNO-LiPA, liver cirrhosis, hepatocellular carcinoma
author_facet Shrikant Dasharath Warkad
Satish Balasaheb Nimse
Keum-Soo Song
Wasun Chantratita
Viroj Pongthanapisith
Laxman Uddhav Nawale
Taisun Kim
author_sort Shrikant Dasharath Warkad
title Performance of 6 HCV genotyping 9G test for HCV genotyping in clinical samples
title_short Performance of 6 HCV genotyping 9G test for HCV genotyping in clinical samples
title_full Performance of 6 HCV genotyping 9G test for HCV genotyping in clinical samples
title_fullStr Performance of 6 HCV genotyping 9G test for HCV genotyping in clinical samples
title_full_unstemmed Performance of 6 HCV genotyping 9G test for HCV genotyping in clinical samples
title_sort performance of 6 hcv genotyping 9g test for hcv genotyping in clinical samples
publisher BMC
series Virology Journal
issn 1743-422X
publishDate 2018-07-01
description Abstract Background A treatment of HCV infection depends on the genotype and sub-genotype. Therefore, accurate HCV genotyping is critical for selecting the appropriate treatment regimen. Method This study included 280 plasma samples to evaluate the performance of 6 HCV Genotyping 9G test. The performance of 6 HCV Genotyping 9G test for accurate detection of HCV 1a, 1b, 2, 3, 4, and 6 genotypes was evaluated by comparing it with LiPA 2.0 assay and sequencing. Results 6 HCV Genotyping 9G test and LiPA 2.0 assay demonstrated 83.9% (n = 235) agreement. 39/45 samples that showed discrepant results between the two tests were analyzed by sequencing. Sequencing genotyped 39 discrepant samples as 0 (HCV 1a), 24 (HCV 1b), 1 (HCV 6f), 12 (HCV 6i), and 2 (HCV-negative). Results of 6 HCV Genotyping 9G test were very similar to the sequencing as it detected 1, 23, 1, 12, and 2 samples as HCV 1a, 1b, 3 & 6a or 6f, 6i or 6n, and negative, respectively. However, LiPA 2.0 assay showed complete disagreement with sequencing, as it did not detect any of these 39 samples correctly. These results indicate that LiPA 2.0 assay has limitations in identifying HCV genotypes 1b, and 6. The sensitivity, specificity, PPV, and NPV of 6 HCV Genotyping 9G test were 99.5, 98.8, 99.5, and 98.8%, respectively. It is important to note that HCV Genotyping 9G test showed 98.3 and 100% sensitivity for HCV 1b and 6 genotyping, respectively. However, LiPA 2.0 assay demonstrated 57.9 and 71.7% sensitivity for these genotypes. Conclusions 6 HCV Genotyping 9G test identifies HCV 1a, 1b, 2, 3, and 6 with good agreement with sequencing. Hence, 6 HCV Genotyping 9G test has a high clinical value because it can provide critical information to physicians and assist them to use the correct drug for efficient hepatitis C treatment.
topic HCV
HCV genotyping
9G DNA technology
INNO-LiPA, liver cirrhosis, hepatocellular carcinoma
url http://link.springer.com/article/10.1186/s12985-018-1017-4
work_keys_str_mv AT shrikantdasharathwarkad performanceof6hcvgenotyping9gtestforhcvgenotypinginclinicalsamples
AT satishbalasahebnimse performanceof6hcvgenotyping9gtestforhcvgenotypinginclinicalsamples
AT keumsoosong performanceof6hcvgenotyping9gtestforhcvgenotypinginclinicalsamples
AT wasunchantratita performanceof6hcvgenotyping9gtestforhcvgenotypinginclinicalsamples
AT virojpongthanapisith performanceof6hcvgenotyping9gtestforhcvgenotypinginclinicalsamples
AT laxmanuddhavnawale performanceof6hcvgenotyping9gtestforhcvgenotypinginclinicalsamples
AT taisunkim performanceof6hcvgenotyping9gtestforhcvgenotypinginclinicalsamples
_version_ 1725989883958263808